Diplomat Pharmacy (DPLO) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Mizuho Securities Remains Sidelined on Diplomat Pharmacy (DPLO) Following 4Q
March 1, 2017 2:17 PM ESTMizuho Securities reiterated a Neutral rating and $17.00 price target on Diplomat Pharmacy (NYSE: DPLO) following the company's 4Q earnings report.
Analyst Ann Hynes commented, "We are reiterating our price target of $17 while lowering our 2017E and 2018E adjusted EPS to $0.62 and $0.75, respectively. We think... More



